Search:
 
This image is of a spacer graphic
NHF Face Book NHF Twitter
+ Login to my NHF
+ NHF Membership
+ Donate to NHF
+ Chapter Center
+ Hechos y Respuestas Rápidas
+ Ethics Advisory Committee
This image is of a spacer graphic
-News
 NHF In The News
 NHF eNotes
 Medical Advisories
 Advocacy and Legislative Updates
 Medical News
 Blood Safety News
 NHF and Community News
-Industry News
 Travel Advisory

 

 

 
REGENX/Chatham to Develop Genetically Based Hemophilia Therapies
 

REGENX BioSciences, LLC recently announced that it has entered into an agreement with Chatham Therapeutics, LLC, an affiliate of Asklepios BioPharmaceutical, Inc. (AskBio), for the development and commercialization of therapies to treat hemophilia A. These therapies would be developed, in part, using REGENX BioSciences’ patented NAV™ rAAV8 vectors. These vectors act as vehicles to deliver customized genetic material that triggers production of the factor VIII protein, which is deficient in people with hemophilia A.

 

AskBio is a clinical development-stage biotechnology company engaged in the development of novel gene therapy-mediated protein therapies using its proprietary Biological Nano Particle (BNP™) technology platform. BNPs can be used to deliver a broad variety of biological material to a cell, including therapeutic genes, vaccines and a number of other materials.

 

“We believe that this collaboration and license option with Chatham is important and will enable the development of NAV rAAV8-based gene delivery treatments for hemophilia,” said Ken Mills, President and Chief Executive Officer of REGENX. “Chatham's development programs combine the outstanding proprietary technologies and expertise of REGENX and AskBio. This agreement represents the continued interest of REGENX to ensure access to our NAV technology for partners that evidence expertise and commitment to development of novel therapies.”

 

Source: REGENX BioSciences news release dated March 8, 2012